Schering misjudges Claritin inventory
Executive Summary
Schering-Plough is reducing its fourth quarter earnings estimate by about $250 mil. (16-18 cents per share) because of "a more-rapid-than-anticipated decline in U.S. prescriptions for Claritin" following the OTC launch in December. Schering says it will not record any sales on shipments of Rx product to wholesalers until an actual prescription is dispensed...